Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPN-812 (Qelbree) in children with ADHD
NCT03247543Phase 3Completed
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Start
- Oct 2017
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of viloxazine in attention deficit hyperactivity disorder (ADHD) (3 arms), sponsored by Supernus Pharmaceuticals, Inc. Primary endpoint: Attention-Deficit/Hyperactivity Disorder Rating Scale-5 at 8 weeks. Started Oct 2017; status: completed.
02
Drugs
viloxazine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT03247543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03247543.